Ethic Inc. Cuts Stock Position in Novo Nordisk A/S $NVO

Ethic Inc. cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 33.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,270 shares of the company’s stock after selling 22,884 shares during the quarter. Ethic Inc.’s holdings in Novo Nordisk A/S were worth $2,354,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Franklin Resources Inc. boosted its stake in Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after buying an additional 13,658,867 shares in the last quarter. Capital International Investors lifted its holdings in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares during the last quarter. Boston Partners purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $310,199,000. Clear Street Group Inc. purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $56,378,000. Finally, Armistice Capital LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $40,841,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $46.96 on Wednesday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $39.24 and a 200-day moving average price of $46.80. The company has a market cap of $209.69 billion, a price-to-earnings ratio of 11.02, a price-to-earnings-growth ratio of 4.20 and a beta of 0.77. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a research note on Tuesday, March 3rd. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: New STEP UP analyses showed the higher-dose Wegovy (7.2 mg) helped early responders achieve nearly 28% average weight loss by week 72, with most of the reduction coming from body fat while preserving muscle health. Article Title
• Positive Sentiment: Additional data presented at the European Congress on Obesity showed Wegovy delivered substantial weight loss in women across menopause stages, along with lower migraine and depression risk signals, broadening the drug’s clinical appeal. Article Title
• Positive Sentiment: CNBC highlighted the same high-dose Wegovy results, which strengthen the case for a premium obesity-treatment label and support Novo Nordisk’s longer-term GLP-1 franchise. Article Title
• Neutral Sentiment: Novo Nordisk also announced that board members, executives, and associated persons reported share transactions, a routine disclosure that does not by itself signal a major fundamental change. Article Title
• Neutral Sentiment: Coverage noting NVO as a trending stock and broader GLP-1 market commentary may be adding attention, but the more important driver is still the company’s obesity-drug data and competitive positioning versus Eli Lilly. Article Title
• Negative Sentiment: Investor caution remains because the GLP-1 market is highly competitive, with Eli Lilly increasingly seen as the dominant rival; pricing pressure and portfolio erosion could cap upside even after the positive Wegovy readouts. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.